Basaglar Insulin

Description

Basaglar Insulin (Insulin Glargine) – Long-Acting Basal Insulin for Diabetes Management

Basaglar Insulin is a reliable, long-acting insulin glargine (100 units/mL) designed to help adults and children with diabetes achieve better blood sugar control throughout the day and night. As a once-daily basal insulin, Basaglar provides steady, peakless glucose-lowering action that mimics the body’s natural background insulin, helping to reduce high blood sugar levels (hyperglycemia) without the pronounced peaks associated with some other insulins.

Key Features and Benefits

• 24-Hour Coverage: Starts working within 1–2 hours after injection and delivers consistent blood sugar control for up to 24 hours, making it ideal for once-daily dosing at the same time each day.
• Proven for Type 1 and Type 2 Diabetes: Indicated to improve glycemic control in adults and pediatric patients (6 years and older) with type 1 diabetes, and in adults with type 2 diabetes. It is often used alongside rapid-acting mealtime insulin or other diabetes medications.
• Convenient Delivery: Available in the easy-to-use Basaglar KwikPen (prefilled disposable pen) and Tempo Pen options. The KwikPen delivers 1–80 units per injection with a simple dial mechanism—no vial or syringe needed for most users.
• Biosimilar to Lantus: Basaglar contains the same active ingredient (insulin glargine) as the reference product Lantus, offering comparable efficacy and safety at a potentially more affordable price point for many patients.
• Steady Action: No pronounced peak, which helps minimize the risk of unexpected blood sugar fluctuations when used as part of a comprehensive diabetes management plan.

How Basaglar Works

Basaglar is a recombinant human insulin analog that lowers blood glucose by stimulating glucose uptake in muscle and fat cells while inhibiting glucose production in the liver. Administered subcutaneously (under the skin), it provides a stable basal insulin foundation—perfect for maintaining target blood sugar levels between meals and overnight.

Important: Basaglar is not for treating diabetic ketoacidosis and should not be mixed or diluted with other insulins.

Typical Usage and Dosing

Your healthcare provider will individualize your Basaglar dosage based on your blood glucose levels, metabolic needs, type of diabetes, and prior insulin use. It is usually injected once daily at the same time every day. Always rotate injection sites (abdomen, thigh, or upper arm) to help prevent lipodystrophy (changes in fat tissue at the injection site).

Note: Closely monitor blood glucose, especially when starting Basaglar or switching from another insulin. Never share your KwikPen with others, even if the needle is changed.

Common Side Effects

Like all insulins, the most common side effect is hypoglycemia (low blood sugar). Other possible effects include injection site reactions, weight gain, swelling, or allergic reactions. Talk to your doctor about managing these and always carry a fast-acting sugar source.

Important Safety Information: Basaglar can cause serious hypoglycemia, which may be life-threatening. Risk increases with changes in dose, meal patterns, physical activity, or when combined with certain other medications. Do not use during episodes of low blood sugar or if you have a known allergy to insulin glargine or any ingredients in Basaglar. Consult your healthcare professional before use, especially if pregnant, breastfeeding, or with kidney/liver issues.

Why Choose Basaglar Insulin?

Patients and healthcare providers often choose Basaglar for its proven effectiveness, user-friendly pen device, and value as a long-acting insulin option. Whether you’re newly diagnosed or switching basal insulins, Basaglar can be an important part of your personalized diabetes treatment plan.

Always consult your doctor or diabetes educator for personalized advice, dosing instructions, and to determine if Basaglar is right for you. This description is for informational purposes only and is not a substitute for professional medical advice.